Drug Approval | May 14, 2026
Pfizer scores landmark EU approval for hemophilia drug HYMPAVZI
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
In the new study, scientists at the University of Virginia used gene-editing techniques to modify GLP-1 receptors in mice to make them more humanlike
Offers a non-surgical treatment option for tricuspid regurgitation, a commonly underdiagnosed heart valve disorder linked to heart failure
The Union Minister reviewed DST-supported SATHI-BHU facility
Expands manufacturing push & locks in major growth deals
The standout story remains Wegovy, particularly its new oral formulation
Doctors highlight rising respiratory risks linked to pollution, seasonal changes, and poor treatment adherence amid increasing asthma burden in India
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
